Pramipexole_product_DataBase

Bioactivity

Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

Invitro

Pramipexole shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM[1].Pramipexole (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3].Pramipexole attenuates levodopa-induced toxicity in mesencephalic cultures[4].

In Vivo

Pramipexole (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals[5].Pramipexole improves neurological recovery[5].Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke[5]. Animal Model:

Name

Pramipexole

CAS

104632-26-0

Formula

C10H17N3S

Molar Mass

211.33

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [2]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71. [3]. Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961. [4]. P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28. [5]. Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860.

PeptideDB

Pramipexole

CAS: 104632-26-0 F: C10H17N3S W: 211.33